Skip to main content
. Author manuscript; available in PMC: 2009 Aug 14.
Published in final edited form as: Cancer Control. 2008 Oct;15(Suppl):40–49. doi: 10.1177/107327480801504s05

Table 3.

New Agents for MDS

Class/Mechanism of Action Agent (Trade)
DNA methyltransferase inhibitor Azacitidine (Vidaza®)
Decitabine (Dacogen)
HDAC Phenylbutyrate
Valproic acid
MS-275
MGCD0103
Vorinostat (Zolinza®)
Farnesyltransferase inhibitor Tipifarnib
Lonafarnib
TNF inhibitor Etanercept (Enbrel®)
Suppression of the abnormal 5q31 clone Lenalidomide (Revlimid®)
Retinoid All-trans retinoic acid (ATRA)
Nucleoside analog Sapacitabine
Glutathione analog TLK199